68Ga-DOTA-CTC1

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug Name68Ga-DOTA-CTC1

Drug Alias NameN/A

ClassificationRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68Ga

Mechanisms of ActionGlypican-3 modulators

TargetsGlypican-3

Therapy Area/IndicationsLiver Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaClinical

Originator CompaniesSmartnuclide Biopharma

China Registration ClassN/A

Develop Information

Active CompaniesSmartnuclide Biopharma

Inactive CompaniesN/A

Active IndicationsLiver Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A